NCT01142089View on ClinicalTrials.gov

Study to Evaluate Safety and Efficacy of Rifamycin SV Multi-Matrix System (MMX) for the Treatment of Traveler's Diarrhea (TD)

PHASE3CompletedINTERVENTIONAL
Enrollment

264

Participants

Timeline

Start Date

May 27, 2010

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions
Traveler's Diarrhea
Interventions
DRUG

Placebo

Placebo (two matching tablets) orally twice daily for 3 days (72 hours).

DRUG

Rifamycin SV MMX

Rifamycin SV MMX® 400 mg (two 200 mg tablets) orally twice daily for 3 days (72 hours).

Trial Locations (12)

6800

Santarus Investigational Site 07, Oaxaca City

23440

Santarus Investigational Site 12, Cabo San Lucas

42670

Santarus Investigational Site 05, Guadalajara

48330

Santarus Investigational Site 11, Puerto Vallarta

62240

Santarus Investigational Site 06, Cuernavaca

71980

Santarus Investigational Site 09, Puerto Escondido

72197

Santarus Investigational Site 08, Puebla City

77500

Santarus Investigational Site 10, Cancún

77760

Santarus Investigational Site 13, Tulum

03001

Santarus Investigational Site 03, Antigua Guatemala

Unknown

Santarus Investigational Site 14, Antigua Guatemala

09001

Santarus Investigational Site 04, Quetzaltenango

Sponsors
All Listed Sponsors
collaborator

Bausch Health Americas, Inc.

INDUSTRY

lead

Cosmo Technologies Ltd

INDUSTRY

NCT01142089 - Study to Evaluate Safety and Efficacy of Rifamycin SV Multi-Matrix System (MMX) for the Treatment of Traveler's Diarrhea (TD) | Biotech Hunter | Biotech Hunter